# Farmacogenomische meta-analyse van bloeddrukrespons op bètablokkers bij Afro-Amerikanen

*geplaatst 2016-03-01 · Hypertensie · Hypertension (Dallas, Tex. : 1979) · doi 10.1161/HYPERTENSIONAHA.115.06345 · https://hartvaat.nl/2016/03/01/farmacogenomische-meta-analyse-van-bloeddrukrespons-op-betablokkers-bij-afro-ame/*

Genoombrede associatiestudie naar genetische determinanten van bloeddrukrespons op bètablokkers bij Afro-Amerikanen met hypertensie. Onderzoekt farmacogenomische verklaringen voor de verminderde effectiviteit van bètablokkers in deze populatie.

## English: Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.

This pharmacogenomic GWAS of blood pressure response to beta-blockers in hypertensive African Americans identified genetic variants that may explain differential drug responsiveness across racial groups.

## Abstract (original, from the publication)

African Americans suffer a higher prevalence of hypertension compared with other racial/ethnic groups. In this study, we performed a pharmacogenomic genome-wide association study of blood pressure (BP) response to β-blockers in African Americans with uncomplicated hypertension. Genome-wide meta-analysis was performed in 318 African American hypertensive participants in the 2 Pharmacogenomic Evaluation of Antihypertensive Responses studies: 150 treated with atenolol monotherapy and 168 treated with metoprolol monotherapy. The analysis adjusted for age, sex, baseline BP and principal components for ancestry. Genome-wide significant variants with P<5×10(-8) and suggestive variants with P<5×10(-7) were evaluated in an additional cohort of 141 African Americans treated with the addition of atenolol to hydrochlorothiazide treatment. The validated variants were then meta-analyzed in these 3 groups of African Americans. Two variants discovered in the monotherapy meta-analysis were validated in the add-on therapy. African American participants heterozygous for SLC25A31 rs201279313 deletion versus wild-type genotype had better diastolic BP response to atenolol monotherapy, metoprolol monotherapy, and atenolol add-on therapy: -9.3 versus -4.6, -9.6 versus -4.8, and -9.7 versus -6.4 mm Hg, respectively (3-group meta-analysis P=2.5×10(-8), β=-4.42 mm Hg per variant allele). Similarly, LRRC15 rs11313667 was validated for systolic BP response to β-blocker therapy with 3-group meta-analysis P=7.2×10(-8) and β=-3.65 mm Hg per variant allele. In this first pharmacogenomic genome-wide meta-analysis of BP response to β-blockers in African Americans, we identified novel variants that may provide valuable information for personalized antihypertensive treatment in this group.

Auteurs: Yan Gong, Zhiying Wang, Amber L Beitelshees, Caitrin W McDonough, Taimour Y Langaee, Karen Hall, Siegfried O F Schmidt, Robert W Curry, John G Gums, Kent R Bailey, Eric Boerwinkle, Arlene B Chapman, Stephen T Turner, Rhonda M Cooper-DeHoff, Julie A Johnson

---
Bron: Hypertension (Dallas, Tex. : 1979), https://doi.org/10.1161/HYPERTENSIONAHA.115.06345. Bijgewerkt 2026-07-03T18:38:22Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.